Welcome to The Visible Embryo

Home- - -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- News Alerts -Contact

Welcome to The Visible Embryo, a comprehensive educational resource on human development from conception to birth.

The Visible Embryo provides visual references for changes in fetal development throughout pregnancy and can be navigated via fetal development or maternal changes.

The National Institutes of Child Health and Human Development awarded Phase I and Phase II Small Business Innovative Research Grants to develop The Visible Embryo. Initally designed to evaluate the internet as a teaching tool for first year medical students, The Visible Embryo is linked to over 600 educational institutions and is viewed by more than ' million visitors each month.


WHO International Clinical Trials Registry Platform
The World Health Organization (WHO) has created a new Web site to help researchers, doctors and patients obtain reliable information on high-quality clinical trials. Now you can go to one website and search all registers to identify clinical trial research underway around the world!



Home

History

Bibliography

Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System

Contact The Visible Embryo

News Alerts Archive

Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.
Content protected under a Creative Commons License.

No dirivative works may be made or used for commercial purposes.

Return To Top Of Page
Pregnancy Timeline by SemestersFemale Reproductive SystemFertilizationThe Appearance of SomitesFirst TrimesterSecond TrimesterThird TrimesterFetal liver is producing blood cellsHead may position into pelvisBrain convolutions beginFull TermWhite fat begins to be madeWhite fat begins to be madeHead may position into pelvisImmune system beginningImmune system beginningPeriod of rapid brain growthBrain convolutions beginLungs begin to produce surfactantSensory brain waves begin to activateSensory brain waves begin to activateInner Ear Bones HardenBone marrow starts making blood cellsBone marrow starts making blood cellsBrown fat surrounds lymphatic systemFetal sexual organs visibleFinger and toe prints appearFinger and toe prints appearHeartbeat can be detectedHeartbeat can be detectedBasic Brain Structure in PlaceThe Appearance of SomitesFirst Detectable Brain WavesA Four Chambered HeartBeginning Cerebral HemispheresEnd of Embryonic PeriodEnd of Embryonic PeriodFirst Thin Layer of Skin AppearsThird TrimesterDevelopmental Timeline
Click weeks 0 - 40 and follow fetal growth
Google Search artcles published since 2007
 
December 16, 2011--------News Archive

Cancer and Fetal Exposure to Carcinogens
Some cancer, chronic diseasse and neurologic disorders can be attributed to fetal exposure to carcinogens as seen in studies of mice.

Gene Discovered for Weaver Syndrome
Research finds new gene for a rare genetic disorder; and also shows gene mutations in fetus cause syndromes- but same mutation later becomes cancer.

Mom's Asthma Inhaler Risks Child Endocrine Issues
Inhaled glucocorticoids for treating asthma in pregnancy are not associated with increased risk of most diseases in babies, but may increase baby's risk for endocrine and metabolic problems.

December 15, 2011--------News Archive

Progesterone Reduces Neonatal Risk
Women with a short cervix should be treated with vaginal progesterone to prevent preterm birth, according to a landmark study by leading obstetricians worldwide.

The Ability to Love Takes Root in Earliest Infancy
The first 12 to 18 months of life may predict your behavior in romantic relationships 20 years later.

Fetal Trachea Correction Increases Survival
A new study reveals that fetal tracheal occlusion (FETO) improves infant survival rate in severe cases of congenital diaphragmatic hernia (CDH).

December 14, 2011--------News Archive

Vaccine Successfully Attacks Breast Cancer in Mice!
Vaccine may have implications for treating ovarian, colorectal and pancreatic cancer.

Mom Weight Before/During Pregnancy Affects Baby
Both pre-pregnant weight and weight gain in pregnancy can predict babies’ birthweight. And high birthweight may also predict an overweight adult.

FoxC1 Gene Discovered to Maintain a Clear Cornea
Gene found in humans and mice that protects transparency of cornea, may lead to new therapy for some causes of blindness.

December 13, 2011--------News Archive

Animal Empathy, How Is It Different From Human?
Neuroscientist says animal models could open door to human feelings.

Clues to How the Pancreas Develops
A rare genetic disorder has given insight into how the pancreas develops. It may be possible to 'program' stem cells to become pancreatic cells.

Mitosis - Making The Right Copy At The Right Time
Scientists show how cells accurately inherit information gained epigenetically.

December 12, 2011--------News Archive

Gene Therapy Against Hereditary Bleeding Disorder
Gene therapy offers first proof that the treatment benefits adults with hemophilia B, reducing need for clotting factor to prevent bleeds.

What Goes On Behind Babies Gift of Gab
From the moment they're born, babies are highly attuned to communicate and motivated to interact. And they're great listeners.

Adult Brains Can Continue to Grow With Learning
London's taxi drivers' must pass a test showing they have memorized that city's complex layout of 25,000 streets – causing structural changes in their brains.

WHO Child Growth Charts


Researchers at Mayo Clinic in Arizona and the University of Georgia (UGA) have developed a vaccine that dramatically reduces tumors in a mouse model that mimics 90 percent of human breast and pancreatic cancer cases — including those that are resistant to common treatments.

The vaccine, described this week in the early edition of the journal Proceedings of the National Academy of Sciences reveals a promising new strategy for treating cancers that share the same distinct carbohydrate signature, including ovarian and colorectal cancers.

When cells become cancerous, the sugars on their surface proteins undergo distinct changes that set them apart from healthy cells. For decades, scientists have tried to enable the immune system to recognize those differences to destroy cancer cells rather than normal cells. But since cancer cells originate within the body, the immune system generally doesn't recognize them as foreign and therefore doesn't mount an attack.

The researchers used unique mice developed by Sandra Gendler, Ph.D., the David F. and Margaret T. Grohne Professor of Therapeutics for Cancer Research at Mayo Clinic in Arizona and co-senior author on the study. Like humans, the mice develop tumors that overexpress a protein known as MUC1 on the surface of their cells. The tumor-associated MUC1 protein is adorned with a distinctive, shorter set of carbohydrates that set it apart from healthy cells.

"This is the first time that a vaccine has been developed that trains the immune system to distinguish and kill cancer cells based on their different sugar structures on proteins such as MUC1," Dr. Gendler says. "We are especially excited about the fact that MUC1 was recently recognized by the National Cancer Institute as one of the three most important tumor proteins for vaccine development."

"This vaccine elicits a very strong immune response," says study co-senior author Geert-Jan Boons, Ph.D., Franklin Professor of Chemistry and a researcher in the UGA Cancer Center and its Complex Carbohydrate Research Center in Athens.

Dr. Gendler says MUC1 is found on more than 70 percent of all cancers that kill. Many cancers, such as breast, pancreatic, ovarian and multiple myeloma, express MUC1 with the shorter carbohydrate on more than 90 percent of cases.

She explains that when cancer occurs, the architecture of the cell changes and MUC1 is produced at high levels, promoting tumor formation. A vaccine directed against MUC1 has tremendous potential to prevent recurrence or as a prophylactic in patients at high risk for particular cancers, Dr. Gendler says. A vaccine also can be used together with standard therapy such as chemotherapy in cancers that cannot be cured by surgery, such as pancreatic cancer.

For the immune system to recognize MUC1 on the tumor cells, it required a special vaccine that had three parts. One part tricks the body into thinking that the cancer cell is a bacterial infection, one part stimulates an antibody response, and one part stimulates a lymphocyte response. If any of the three components were omitted, the vaccine did not work as well.

Dr. Boons notes that MUC1 is also overexpressed in 90 percent of the subset of patients who are not responsive to hormonal therapy, such as tamoxifen or aromatase inhibitors, or the drug Herceptin. These so-called triple-negative tumors are extremely aggressive and difficult to treat, Dr. Boons says, and a new treatment option is urgently needed.

"In the U.S. alone, there are 35,000 patients diagnosed every year whose tumors are triple-negative," Dr. Boons says. "So we might have a therapy for a large group of patients for which there is currently no drug therapy aside from chemotherapy."

Dr. Gendler and her colleagues are currently testing the vaccine's effectiveness against human cancer cells in culture and are planning to assess toxicity. If all goes well, phase I clinical trials to test the safety of the vaccine could begin by late 2013.

Co-first authors on the paper are Vani Lakshminarayanan, Ph.D., at Mayo Clinic in Arizona, and Pamela Thompson at the University of Georgia. Additional authors include Margreet Wolfert, Ph.D. and Therese Buskas, Ph.D., both from UGA; and Judy Bradley, Latha Pathangey, Cathy Madsen and Peter Cohen, M.D., all from Mayo Clinic in Arizona.

The research was funded by the National Cancer Institute, the Mayo Breast Specialized Program of Research Excellence (SPORE) Grant and the Mayo Pancreas SPORE Grant.

Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit MayoClinic.com or MayoClinic.org/news.

Original article: http://www.mayoclinic.org/news2011-sct/6614.html